MiMedx Group (NASDAQ:MDXG) Hits New 1-Year Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG)’s stock price reached a new 52-week low on Friday . The company traded as low as $4.35 and last traded at $4.3550, with a volume of 156572 shares trading hands. The stock had previously closed at $4.38.

Analysts Set New Price Targets

MDXG has been the topic of a number of analyst reports. UBS Group set a $10.00 price objective on MiMedx Group in a report on Monday, February 23rd. Citizens Jmp assumed coverage on shares of MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 target price for the company. Lake Street Capital dropped their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 20th. Cantor Fitzgerald cut their price target on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Finally, Mizuho cut their price target on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.60.

MiMedx Group Price Performance

The company has a market cap of $650.74 million, a price-to-earnings ratio of 13.69 and a beta of 1.60. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average price of $5.24 and a two-hundred day moving average price of $6.39.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The business had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. On average, equities analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors have recently modified their holdings of MDXG. Legato Capital Management LLC grew its holdings in shares of MiMedx Group by 18.5% during the 3rd quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock valued at $121,000 after acquiring an additional 2,708 shares in the last quarter. HighMark Wealth Management LLC increased its stake in shares of MiMedx Group by 5.4% in the third quarter. HighMark Wealth Management LLC now owns 55,878 shares of the company’s stock worth $390,000 after acquiring an additional 2,878 shares during the last quarter. SkyView Investment Advisors LLC raised its holdings in shares of MiMedx Group by 3.6% during the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after acquiring an additional 3,032 shares in the last quarter. Rafferty Asset Management LLC raised its holdings in shares of MiMedx Group by 4.6% during the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock worth $469,000 after acquiring an additional 3,064 shares in the last quarter. Finally, Aviva PLC boosted its position in MiMedx Group by 4.7% during the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock valued at $482,000 after purchasing an additional 3,211 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.